Skip to content
Trial Eligibility
Menu

Evaluation of Patients With HAM/TSP

NCT00001778

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. The purpose of this protocol is to study the natural history of HAM/TSP by monitoring clinical progression of patients longitudinally. Additionally, we will attempt to define the virological and immunological changes of HAM/TSP. Study Population: Patients with HAM/TSP who fulfill World Health Organization diagnostic criteria are eligible to participate in this protocol.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • HTLV-I Infection
  • Tropical Spastic Paraparesis

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
18 to 120 years
Sex
All
Healthy volunteers
Accepted
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Last updated on ClinicalTrials.gov
September 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Maryland · 1

  • National Institutes of Health Clinical Center · Bethesda, MD

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.